Extended Survival in Patients With Non-Small-Cell Lung Cancer-Associated Brain Metastases in the Modern Era.
Assaf BergerReed MullenKenneth BernsteinJuan Diego AlzateJoshua S SilvermanErik P SulmanBernadine R DonahueAbraham ChachouaElaine ShumVamsidhar VelchetiJoshua SabariJohn G GolfinosDouglas KondziolkaPublished in: Neurosurgery (2023)
Long-term survival in patients with brain metastases from NSCLC is feasible in the current era of SRS when combined with the use of effective targeted therapeutics. Of those living ≥5 years, the chance for living with stable disease without the need for active treatment for ≥3 years was 16%.